SWM
TARO

SVA Wealth Management’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

SVA Wealth Management’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,020
Closed -$312K – 214
2015
Q4 		$312K Hold
2,020
– – 0.05% 180
2015
Q3 		$289K Buy
+2,020
New +$282K 0.05% 174

Other funds holding TARO

Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCM
Greywolf Capital Management Purchase, New York $67.3M AUM 100.05% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
FCH
Freestone Capital Holdings Seattle, Washington $3.3B AUM 21.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SVA Wealth Management's TARO Position: Q1 2016 in Review

SVA Wealth Management sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q1 2016, closing a stake of 2,020 shares — an estimated $312K sold.

SVA Wealth Management first reported a position in TARO in Q3 2015 and held it in 2 quarters. The position peaked at $312K in Q4 2015. 167 funds tracked by Wall St. Rank hold TARO as of Q1 2016.

  • SVA Wealth Management reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q1 2016 after selling out during the quarter.
  • SVA Wealth Management sold 2,020 Taro Pharmaceutical Industries Ltd. shares in Q1 2016, an estimated $312K.
  • SVA Wealth Management first reported a position in Taro Pharmaceutical Industries Ltd. in Q3 2015 and held it in 2 quarters.
  • SVA Wealth Management's Taro Pharmaceutical Industries Ltd. position peaked at $312K in Q4 2015.
  • 167 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q1 2016.

Based on SVA Wealth Management's 13F filing for Q1 2016, filed 9 May 2016.